Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 2/20 | 0.44 |
| ▸ | MDM4 | O15151 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29431078 | 1.00 | MDM2 (0.44) | MDM2MDM4TP53TLR2BACE1 | |
| SCHEMBL12658043 | 1.00 | MDM2 (0.44) | MDM2MDM4TP53TLR2BACE1 | |
| SCHEMBL30412459 | 1.00 | MDM2 (0.44) | MDM2MDM4TP53TLR2BACE1 | |
| SCHEMBL29511122 | 0.93 | MDM4 (0.45) | MDM2MDM4TP53TLR2BACE1 | |
| SCHEMBL30025559 | 0.93 | MDM4 (0.45) | MDM2MDM4TP53TLR2BACE1 | |
| SCHEMBL16412291 | 0.93 | MDM4 (0.45) | MDM2MDM4TP53TLR2BACE1 | |
| SCHEMBL30097312 | 0.93 | MDM4 (0.45) | MDM2MDM4TP53TLR2BACE1 | |
| SCHEMBL31292141 | 0.93 | MDM4 (0.45) | MDM2MDM4TP53TLR2BACE1 | |
| SCHEMBL20732314 | 0.93 | MDM4 (0.45) | MDM2MDM4TP53TLR2BACE1 | |
| SCHEMBL29401629 | 0.91 | MDM4 (0.44) | MDM2MDM4TP53BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3972649-B1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| US-20250276074-A1 | BRM AND BRG1 TARGETING ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | PRELUDE THERAPEUTICS INCORPORATED | 2025-09-04 | — | — | US | disclosed |
| EP-4326741-A1 | CYCLOPOLYPHOSPHAZENES, RELATED METHODS OF PREPARATION AND METHODS OF USE | University of Saskatchewan (CA) | 2024-02-28 | — | — | EP | disclosed |
| US-20240042051-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | LES LABORATOIRES SERVIER (FR) | 2024-02-08 | — | — | US | disclosed |
| EP-4251208-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2023-10-04 | — | — | EP | disclosed |
| US-20230092679-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-03-23 | — | — | US | disclosed |
| US-20230081720-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-03-16 | — | — | US | disclosed |
| WO-2022221959-A1 | CYCLOPOLYPHOSPHAZENES, RELATED METHODS OF PREPARATION AND METHODS OF USE | UNIVERSITY OF SASKATCHEWAN (CA) | 2022-10-27 | — | — | WO | disclosed |
| US-20220265842-A1 | ANTI-CD40 ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2022-08-25 | — | — | US | disclosed |
| WO-2022115451-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| EP-3972651-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| EP-3972649-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230092679-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MCL1, BCL9, BAK1 | MDM2 528/4885MDM4 978/4885TP53 166/4885 |
| US-20230081720-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MCL1, CD74, CD99 | MDM2 533/4885MDM4 682/4885TP53 56/4885 |
| US-20240042051-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MCL1, CD58, LENG8 | MDM2 1619/4885MDM4 1244/4885TP53 148/4885 |
| US-20220265842-A1 | ANTI-CD40 ANTIBODY DRUG CONJUGATES | CD40, CD40LG, FCGRT | MDM2 1711/4885MDM4 3145/4885TP53 828/4885 |
| US-20250276074-A1 | BRM AND BRG1 TARGETING ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | CRBN, RBX1, SMARCE1 | MDM2 86/4885MDM4 912/4885TP53 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.